JGJoann F. Gruber

Joann F. Gruber

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Joann F. Gruber has a total of 130 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Safety Monitoring of Multiple Health Outcomes Following 2023–2024 COVID-19 Vaccination among Medicare Beneficiaries Aged 65 Years and Older in the United States

    by Joann F. Gruber, Michelle Ondari, Carla E. Zelaya, Chunyi Xia, Fengdi Zhang, Jessica Rose Hervol, Jin Ye, Meng Chen, Yutong Qin, Mao Hu, et al.

    Background: COVID-19 vaccines are well-established as safe. However, continued surveillance of COVID-19 vaccines is important to ensure the safety of newly formulated vaccines. This study evaluated the association between vaccination with 2023-2024 formula COVID-19 vaccines and multiple health outcomes among Medicare beneficiaries aged 65 years and older in the United States. Methods: The study used health plan data from the Medicare Fee-for-Service (FFS) claims database and extended from September 2023 to April 2024. We monitored the uptake of 2023–2024 COVID-19 vaccines (Pfizer-BioNTech, Moderna, Novavax), and where case counts were available, we used a self-controlled case series design to assess the association between vaccination and prespecified health outcomes. We used conditional Poisson regression to estimate incidence rate ratios (IRRs), attributable risks (ARs) and corresponding 99% confidence intervals (CIs). Analyses were adjusted for outcome seasonality, event-dependent observation time for outcomes with high case fatality rates, and outcome misclassification where feasible. Results: Approximately 7.6 million Medicare FFS beneficiaries received a 2023–2024 COVID-19 vaccination. There was an even distribution of people who received Pfizer-BioNTech (3,689,356; 48.80%) or Moderna (3,841,245; 50.80%) vaccinations and very few who received Novavax (30,171; 0.40%). There was a statistically significant elevation in anaphylaxis risk associated with 2023–2024 Pfizer-BioNTech vaccines in the seasonality-adjusted analysis (IRR: [99% CI: 1.07, 15.30]) that was no longer statistically significant after accounting for potential outcome misclassification (IRR: 3.90 [99% CI: 0.49, 30.90]). Anaphylaxis cases attributable to 2023–2024 Pfizer-BioNTech vaccination were rare (AR per 100,000 doses: 0.09 [99% CI: −0.08, 0.25]). No other statistically significant elevations in risk were observed. Conclusion: There were no new safety signals identified following 2023–2024 COVID-19 vaccinations among U.S. Medicare beneficiaries aged 65 years and older. A potential, but rare, elevation in anaphylaxis incidence rates following 2023–2024 Pfizer-BioNTech COVID-19 vaccination was observed. HIGHLIGHTS: We studied 7,560,772 Medicare enrollees ≥65 years old who received 2023–2024 COVID-19 vaccines No new safety signals were identified in the Medicare population ≥65 years old A potential–but rare–elevation in anaphylaxis risk was associated with vaccination No increased risk of any other prespecified health outcomes was found


  • Open Access

    Safety Monitoring of Mpox Vaccines in Adults Aged 18–64 Years during the 2022 Mpox Outbreak in the U.S.

    by Joann F. Gruber, Kathryn Matuska, Carla E. Zelaya, Jing Wang, Cheryl N McMahill-Walraven, Lauren Peetluck, Alex Secora, Shwetha Krishnakumar, Mao Hu, Kandace L. Amend, et al.

    Two vaccines (JYNNEOS; ACAM2000) were available in the United States to prevent mpox during the 2022 clade II mpox outbreak with the majority of people receiving JYNNEOS. As part of the Biologics Effectiveness and Safety (BEST) Initiative, FDA monitored the safety of JYNNEOS using three commercial health plan claims databases supplemented with local and state Immunization Information System data. We assessed vaccine uptake, described the vaccinated population, monitored rates of 11 potential adverse events (AEs) following vaccination, and compared the observed AE rates to expected background rates. There were 152,001 JYNNEOS doses administered. Of the 92,340 people receiving at least one JYNNEOS dose, most were males (93.1%), aged 25–44 years (63.3%), lived in urban areas (98.7%), and 64.2% received a second dose. AE rates following JYNNEOS doses were similar to expected background rates. Additional safety studies of larger vaccinated populations may be needed to evaluate rare AEs including myocarditis/pericarditis.

  • Open Access

    Evaluating the Risk of Cardiovascular Adverse Events and Appendicitis After COVID-19 Diagnosis in Adults in the United States: Implications of the Start of Follow-Up

    by J. Bradley Layton, Arnstein Lindaas, Stella G. Muthuri, Patricia C. Lloyd, Morgan M. Richey, Joann F. Gruber, Hai Lyu, Mollie M. McKillop, Lisa S. Kowarski, Christine Bui, et al.

    Purpose: This study evaluated the association between coronavirus disease 2019 (COVID-19) diagnosis and adverse events (AEs), including cardiovascular AEs and appendicitis, in US adults before the introduction of COVID-19 vaccines. Real-world studies of AEs after COVID-19 suggest that diagnoses of AEs and COVID-19 frequently occur on the same day and may be a source of bias. Methods: Cohort and self-controlled risk interval (SCRI) designs were used in 2 US administrative claims data sources—Merative™ MarketScan® (ages 18-64 years) and Medicare (ages ≥ 65 years). AEs included stroke (nonhemorrhagic and hemorrhagic), acute myocardial infarction, myocarditis/pericarditis, deep vein thrombosis, pulmonary embolism (PE), disseminated intravascular coagulation (DIC), unusual-site and common-site thrombosis with thrombocytopenia syndrome, and appendicitis. In cohort analyses, weighted hazard ratios (HRs) and 95% confidence intervals (CIs) compared adults with a COVID-19 diagnosis and matched comparators. In SCRI analysis, relative incidences (RIs) and 95% CIs compared risk and reference windows within individuals. Analyses were performed starting follow-up on Time 0 and Day 1. Results: For cardiovascular AEs, all estimates starting follow-up on Day 1 were above 1.0 in both data sources. For cohort analyses, the strongest associations were for inpatient PE in both databases: MarketScan, HR=8.65 (95% CI, 6.06-12.35), Medicare HR=3.06 (95% CI, 2.88-3.26). For SCRI analyses, the strongest association in MarketScan was for DIC: RI=32.28 (95% CI, 17.06-61.09) and in Medicare was for myocarditis/pericarditis: RI=4.53 (95% CI, 3.89-5.27). AEs diagnosed concurrently with COVID-19 (ie, on Time 0) were common; including Time 0 in follow-up/risk windows resulted in higher RIs, as well as higher HRs for some AEs. However, some AEs (eg, stroke) were more common on Time 0 in the comparator group resulting in lower HRs. Conclusion: COVID-19 diagnoses had moderate to strong associations with cardiovascular AEs and weak or inconsistent associations with appendicitis, although estimates varied by design and methodology.

  • Open Access

    Effectiveness Over Time of a Primary Series of the Original Monovalent COVID-19 Vaccines in Adults in the United States

    by J. Bradley Layton, Patricia C. Lloyd, Lauren S. Peetluk, Yixin Jiao, Djeneba Audrey Djibo, Joann F. Gruber, Jie Deng, Christine Bui, An-Chi Lo, Rachel P. Ogilvie, et al.

    With data from 2 US claims databases (Optum, CVS Health) supplemented with Immunization Information System COVID 19 vaccine records, we evaluated overall and time-specific vaccine effectiveness (VE) of an initial primary series for 3 monovalent COVID 19 vaccines—BNT162b2, mRNA-1273, and JNJ-7836735—in adults (18-64 years). Vaccinated individuals were matched to unvaccinated comparators, and we estimated VE against any medically diagnosed COVID 19 and hospital/emergency department (ED)-diagnosed COVID 19. Additionally, we estimated VE by era of predominant variants, in subgroups, and compared across vaccine brands. The cohorts consisted of 341,097 (Optum) and 1,151,775 (CVS Health) matched pairs for BNT162b2; 201,604 (Optum) and 651,545 (CVS Health) for mRNA-1273; and 49,285 (Optum) and 149,813 (CVS Health) for JNJ-7836735. Summary VE estimates from meta-analysis against hospital/ED-diagnosed COVID 19 were: BNT162b2, 77% (95% CI, 76%-78%); mRNA-1273, 84% (95% CI, 83%-85%), JNJ-7836735 66% (95% CI, 63%-68%). VE estimates were higher for hospital/ED-diagnosed COVID 19 than for medically diagnosed COVID-19, and VE estimates were highest in adults receiving mRNA-1273 for both outcomes. VE was sustained for approximately 7 months for medically-diagnosed and up to 9 months for hospital/ED-diagnosed COVID 19. VE differed by brand and variant era. Additional real-world research is needed as new variants and recommendations for updated vaccines have evolved.

  • Assessment of potential adverse events following the 2022–2023 seasonal influenza vaccines among U.S. adults aged 65 years and older

    by Xiangyu Chianti Shi, Joann F. Gruber, Michelle Ondari, Patricia C. Lloyd, Pablo Freyria Duenas, Tainya C. Clarke, Gita Nadimpalli, Sylvia Cho, Laurie Feinberg, Mao Hu, et al.


  • Open Access

    Safety Monitoring of Bivalent COVID-19 mRNA Vaccines Among Recipients 6 months and Older in the United States

    by Patricia C. Lloyd, Elizabeth R. Smith, Joann F. Gruber, Michelle Ondari, Hui Lee Wong, Mao Hu, Tainya C. Clarke, Rowan McEvoy, Kandace L. Amend, Daniel C. Beachler, et al.

    Active monitoring of health outcomes after COVID-19 vaccination provides early detection of rare outcomes post-licensure. Objective To evaluate health outcomes following bivalent COVID-19 Pfizer-BioNTech (BNT162b2) and Moderna (mRNA-1273.222) vaccination among individuals 6 months and older in the United States. Design Monthly monitoring of health outcomes from August 2022 to July 2023 in four administrative claims databases. Descriptive analyses monitored vaccine uptake, outcome counts and coadministration of bivalent COVID-19 and influenza vaccines. Sequential analyses tested for elevated risk of each outcome in a prespecified post-vaccination risk interval, or a period of hypothesized elevation based on clinical guidance, compared to a historical baseline. Participants and Exposures Persons 6 months and older who received a bivalent COVID-19 BNT162b2 or mRNA-1273.222 vaccine during the study period, with continuous enrollment in a medical insurance plan from the start of an outcome-specific clean interval to the COVID-19 vaccination date. Vaccines were identified using product-specific codes from medical coding systems. Health Outcomes Twenty outcomes were monitored in BNT162b2 vaccine recipients 6 months-4 years, and mRNA-1273.222 vaccine recipients 6 months-5 years. Twenty-one outcomes were monitored in BNT162b2 vaccine recipients 5-17 years and mRNA-1273.222 vaccine recipients 6-17 years. Eighteen outcomes were monitored in persons 18 years and older for both mRNA vaccines. Results Overall, 13.9 million individuals 6 months and older received a single bivalent COVID-19 mRNA vaccine. The statistical threshold for a signal was met for two outcomes in one database: anaphylaxis following bivalent BNT162b2 and mRNA-1273.222 vaccines in persons 18-64 years and myocarditis/pericarditis following bivalent BNT162b2 vaccines in individuals 18-35 years. There were no signals identified in young children. Conclusions Results were consistent with prior observations from published studies on COVID-19 vaccine safety. This study supports the safety profile of bivalent COVID-19 mRNA vaccines and the conclusion that the benefits of vaccination outweigh the risks.


  • Open Access

    Effectiveness of monovalent COVID-19 booster/additional vaccine doses in the United States

    by J. Bradley Layton, Lauren Peetluk, Hui Lee Wong, Yixin Jiao, Djeneba Audrey Djibo, Christine Bui, Patricia C. Lloyd, Joann F. Gruber, Michael Miller, Rachel P. Ogilvie, et al.


  • Open Access

    Assessment of Potential Adverse Events Following the 2022–2023 Seasonal Influenza Vaccines Among U.S. Adults Aged 65 Years and Older

    by Xiangyu (Chianti) Shi, Joann F. Gruber, Michelle Ondari, Patricia C. Lloyd, Pablo Freyria Duenas, Tainya C. Clarke, Gita Nadimpalli, Sylvia Cho, Laurie Feinberg, Mao Hu, et al.

    Background: While safety of influenza vaccines is well-established, some studies have suggested potential associations between influenza vaccines and certain adverse events (AEs). This study examined the safety of the 2022–2023 influenza vaccines among U.S. adults ≥ 65 years. Methods: A self-controlled case series compared incidence rates of anaphylaxis, encephalitis/encephalomyelitis, Guillain Barré-Syndrome (GBS), and transverse myelitis following 2022–2023 seasonal influenza vaccinations (i.e., any, high-dose or adjuvanted) in risk and control intervals among Medicare beneficiaries ≥ 65 years. We used conditional Poisson regression to estimate incidence rate ratios (IRRs) and 95% confidence intervals (CIs) adjusted for event-dependent observation time, seasonality, and outcome misclassification. For AEs with any statistically significant associations, we stratified results by concomitant vaccination status. Results: Among 12.7 million vaccine recipients, we observed 76 anaphylaxis, 276 encephalitis/encephalomyelitis, 134 GBS and 75 transverse myelitis cases. Only rates of anaphylaxis were elevated in risk compared to control intervals. With all adjustments, an elevated, but non-statistically significant, anaphylaxis rate was observed following any (IRR: 2.40, 95% CI: 0.96–6.03), high-dose (IRR: 2.31, 95% CI: 0.67–7.91), and adjuvanted (IRR: 3.28, 95% CI: 0.71–15.08) influenza vaccination; anaphylaxis IRRs were 2.54 (95% CI: 0.49–13.05) and 1.64 (95% CI: 0.38–7.05) for those with and without concomitant vaccination, respectively. Conclusions: Rates of encephalitis/encephalomyelitis, GBS, or transverse myelitis were not elevated following 2022–2023 seasonal influenza vaccinations among U.S. adults ≥ 65 years. There was an increased rate of anaphylaxis following influenza vaccination that may have been influenced by concomitant vaccination.


  • Open Access

    Effectiveness of BNT162b2 COVID-19 Vaccination in Children Aged 5–17 Years in the United States

    by Rachel P. Ogilvie, J. Bradley Layton, Patricia C. Lloyd, Yixin Jiao, Djeneba Audrey Djibo, Hui Lee Wong, Joann F. Gruber, Ron Parambi, Jie Deng, Michael Miller, et al.

    Importance COVID-19 vaccines are authorized for use in children in the United States; real-world assessment of vaccine effectiveness in children is needed. Objective To estimate the effectiveness of receiving a complete primary series of monovalent BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine in US children. Design A cohort study of children aged 5–17 years vaccinated with BNT162b2 matched with unvaccinated children. Setting Participants identified in Optum and CVS Health insurance administrative claims databases were linked with Immunization Information System (IIS) COVID-19 vaccination records from 16 US jurisdictions between December 11, 2020, and May 31, 2022 (end date varied by database and IIS). Participants Vaccinated children were followed from their first BNT162b2 dose and matched to unvaccinated children on calendar date, US county of residence, and demographic and clinical factors. Censoring occurred if vaccinated children failed to receive a timely dose 2 or if unvaccinated children received any dose. Exposure BNT162b2 vaccinations were identified using IIS vaccination records and insurance claims. Main Outcomes and Measures Two COVID-19 outcome definitions were evaluated: COVID-19 diagnosis in any medical setting and COVID-19 diagnosis in hospitals/emergency departments (EDs). Propensity score-weighted hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated with Cox proportional hazards models, and vaccine effectiveness (VE) was estimated as 1 minus HR. VE was estimated overall, within age subgroups, and within variant-specific eras. Sensitivity, negative control, and quantitative bias analyses evaluated various potential biases. Results There were 453,655 eligible vaccinated children one-to-one matched to unvaccinated comparators (mean age 12 years; 50% female). COVID-19 hospitalizations/ED visits were rare in children, regardless of vaccination status (Optum, 41.2 per 10,000 person-years; CVS Health, 44.1 per 10,000 person-years). Overall, vaccination was associated with reduced incidence of any medically diagnosed COVID-19 (meta-analyzed VE = 38% [95% CI, 36%-40%]) and hospital/ED–diagnosed COVID-19 (meta-analyzed VE = 61% [95% CI, 56%-65%]). VE estimates were lowest among children 5–11 years and during the omicron variant era. Conclusions and Relevance Receipt of a complete BNT162b2 vaccine primary series was associated with overall reduced medically diagnosed COVID-19 and hospital/ED–diagnosed COVID-19 in children; observed VE estimates differed by age group and variant era. Question Does receiving a complete primary series of monovalent BNT162b2 COVID-19 vaccine reduce COVID-19 diagnoses and ED visits/hospitalizations in children aged 5–17 years? Findings In this cohort study evaluating vaccination records and medical encounters from 827,149 children, recipients of a complete primary series of BNT162b2 generally had lower rates of COVID-19 diagnoses and ED visits/hospitalizations than unvaccinated children. Vaccine effectiveness was lower in children aged 5–11 years and during omicron variant predominance. Meaning Receiving a primary series of monovalent BNT162b2 COVID-19 vaccine is effective in preventing COVID-19 diagnoses; changing variants and younger age groups may require further evaluations.

  • Yersinia enterocolitica Outbreak Associated with Pasteurized Milk

    by Joann F. Gruber, Sheri Morris, Kimberly A. Warren, Kelly E. Kline, Betsy Schroeder, Lisa Dettinger, Brigitte Husband, Kerry Pollard, Carina Davis, Judith Miller, et al.

    In July 2019, we investigated a cluster of Yersinia enterocolitica cases affecting a youth summer camp and nearby community in northeastern Pennsylvania. After initial telephone interviews with camp owners and community members, we identified pasteurized milk from a small dairy conducting on-site pasteurization, Dairy A, as a shared exposure. We conducted site visits at the camp and Dairy A where we collected milk and other samples. Samples were cultured for Y. enterocolitica. Clinical and nonclinical isolates were compared using molecular subtyping. We performed case finding, conducted telephone interviews for community cases, and conducted a cohort study among adult camp staff by administering an online questionnaire. In total, we identified 109 Y. enterocolitica cases. Consumption of Dairy A milk was known for 37 (34%); of these, Dairy A milk was consumed by 31 (84%). Dairy A had shipped 214 gallons of pasteurized milk in 5 weekly shipments to the camp by mid-July. Dairy A milk was the only shared exposure identified between the camp and community. Y. enterocolitica was isolated from Dairy A unpasteurized milk samples. Five clinical isolates from camp members, two clinical isolates from community members, and nine isolates from unpasteurized milk were indistinguishable by whole-genome sequencing. The risk for yersinosis among camp staff who drank Dairy A milk was 5.3 times the risk for those who did not (95% confidence interval: 1.6–17.3). Because Dairy A only sold pasteurized milk, pasteurized milk was considered the outbreak source. We recommend governmental agencies and small dairies conducting on-site pasteurization collaborate to develop outbreak prevention strategies.